C
Christopher Bangard
Researcher at University of Cologne
Publications - 69
Citations - 1758
Christopher Bangard is an academic researcher from University of Cologne. The author has contributed to research in topics: Radiofrequency ablation & Aspergillosis. The author has an hindex of 20, co-authored 66 publications receiving 1507 citations.
Papers
More filters
Journal ArticleDOI
Dissociating cognitive from affective theory of mind: A TMS study
Elke Kalbe,Marius Schlegel,Alexander T. Sack,Dennis A. Nowak,Manuel Dafotakis,Christopher Bangard,Matthias Brand,Simone G. Shamay-Tsoory,Oezguer A. Onur,Josef Kessler +9 more
TL;DR: These findings provide evidence for the functional independence of cognitive from affective ToM and point to an important role of the right DLPFC within neural networks mediating cognitive ToM.
Journal ArticleDOI
Functional Outcome Following Stroke Thrombectomy in Clinical Practice
Frank A. Wollenweber,Steffen Tiedt,Anna Alegiani,Burkhard Alber,Christopher Bangard,Jörg Berrouschot,Felix J. Bode,Tobias Boeckh-Behrens,Georg Bohner,Albrecht Bormann,Michael Braun,Franziska Dorn,Bernd Eckert,Fabian Flottmann,Gerhard F. Hamann,Karl-Heinz Henn,Moriz Herzberg,Andreas Kastrup,Lars Kellert,Christoffer Kraemer,Lars Udo Krause,Manuel Lehm,Jan Liman,Stephan Lowens,Anastasios Mpotsaris,Panagiotis Papanagiotou,Martina Petersen,Gabor C. Petzold,Gabor C. Petzold,Waltraud Pfeilschifter,Marios-Nikos Psychogios,Arno Reich,Regina von Rennenberg,Joachim Röther,Jan-Hendrik Schäfer,Eberhard Siebert,Andreas Siedow,Laszlo Solymosi,Sven Thonke,Marlies Wagner,Silke Wunderlich,Sarah Zweynert,Christian H. Nolte,Christian Gerloff,Götz Thomalla,Martin Dichgans,Martin Dichgans,Jens Fiehler +47 more
TL;DR: Mortality appears to be greater in the daily routine than otherwise reported by authors of large randomized trials and high rates of favorable outcome can be achieved on a countrywide scale by endovascular treatment.
Journal ArticleDOI
Clinical effectiveness of posaconazole prophylaxis in patients with acute myelogenous leukaemia (AML): a 6 year experience of the Cologne AML cohort
Jörg Janne Vehreschild,Maria J. G. T. Rüping,Hilmar Wisplinghoff,Fedja Farowski,Angela Steinbach,R. Sims,A. Stollorz,Karl-Anton Kreuzer,Michael Hallek,Christopher Bangard,Oliver A. Cornely +10 more
TL;DR: After introduction of posaconazole prophylaxis for patients with AML, the number of febrile days, the incidence rate of IFDs and aspergillosis and the duration of hospitalization decreased significantly.
Journal ArticleDOI
Early relapses in primary CNS lymphoma after response to polychemotherapy without intraventricular treatment: results of a phase II study
Hendrik Pels,Annika Juergens,Axel Glasmacher,Holger Schulz,Andreas Engert,Michael Linnebank,Gabriele Schackert,Heinz Reichmann,Frank Kroschinsky,Marlies Vogt-Schaden,Gerlinde Egerer,Udo Bode,Carlo Schaller,Monika Lamprecht,Peter Hau,Martina Deckert,Rolf Fimmers,Christopher Bangard,Ingo G.H. Schmidt-Wolf,Uwe Schlegel +19 more
TL;DR: In PCNSL patients <60 years, polychemotherapy without intraventricular treatment results in a high response rate, but is associated with early relapses in the majority of cases, in contrast to the results achieved with the same protocol but with intravent cardiac treatment.
Journal ArticleDOI
Brentuximab vedotin for relapsed or refractory CD30+ hematologic malignancies: the German Hodgkin Study Group experience
Achim Rothe,Stephanie Sasse,Helen Goergen,Dennis A. Eichenauer,Andreas Lohri,Ulrich Jäger,Christopher Bangard,Boris Böll,Michael von Bergwelt Baildon,Sebastian Theurich,Peter Borchmann,Andreas Engert +11 more
TL;DR: A retrospective analysis supports the previously reported excellent therapeutic efficacy of brentuximab vedotin in heavily pretreated CD30(+) malignancies.